Previous 10 |
Gainers: VivoPower International (NASDAQ: VVPR ) +52% . ENDRA Life Sciences (NASDAQ: NDRA ) +41% . Leap Therapeutics (NASDAQ: LPTX ) +31% . Stitch Fix (NASDAQ: SFIX ) +30% . Seelos Therapeutics (NASDAQ: SEEL ) +26% . Key Energy Services (NYSE: KEG ) +24% . Chaparral Energy (NYS...
The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with this Read more ...
Jounce Therapeutics (JNCE) Q4 2018 Earnings Conference Call March 6, 2019 08:00 ET Company Participants Komal Joshi - Investor Relations Rich Murray - President and Chief Executive Officer Beth Trehu - Chief Medical Officer Kim Drapkin - Chief Financial Officer Conference Ca...
Jounce Therapeutics ( JNCE ) Q4 results : Revenues: $20.1M (+54.6%). More news on: Jounce Therapeutics, Healthcare stocks news, Earnings news and commentary, , Read more ...
Jounce Therapeutics (NASDAQ: JNCE ): Q4 GAAP EPS of -$0.06 beats by $0.30 . More news on: Jounce Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
- New data from two programs to be presented at AACR - - New Phase 2 studies to be initiated in 2019 supported by established safety from dose escalation cohorts of vopratelimab (JTX-2011), with ipilimumab and with pembrolizumab - - Ended 2018 with $195.9 million in cash, cash equ...
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and...
CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2018 fi...
ICONIC Clinical Data Demonstrates Improved PFS/OS in Patients with Emergence of JTX-2011 Mechanistic Biomarker (ICOS high CD4 T cells) Company to Host Investor Event and Live Webcast on Tuesday, April 2, 2019 CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, ...
News, Short Squeeze, Breakout and More Instantly...
Jounce Therapeutics Inc. Company Name:
JNCE Stock Symbol:
NASDAQ Market:
Jounce Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Co...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or t...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE)...